Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1389 GIGA-564 a third generation anti CTLA 4 with minimal ability to block CTLA 4 binding to B7 ligands has enhanced efficacy but reduced toxicity compared to ipilimumab in preclinical models
Compose a Response to This Article
Other responses
No responses have been published for this article.